肿瘤突变负荷用于预测恶性肿瘤患者预后的研究进展
Research Progress of Tumor Mutational Burden in Predicting Prognosis of Patients with Malignant Tumors
摘要: 随着免疫检查点抑制剂(immune checkpoint inhibitor, ICI)在多种恶性肿瘤中的应用，免疫治疗已成为肿瘤治疗的研究焦点。最近，肿瘤突变负荷(tumor mutational burden, TMB)已逐渐成为多种恶性肿瘤免疫治疗选择的可靠生物标志物。本文主要对TMB在恶性肿瘤免疫治疗中相关研究以及与其他生物标志物联合预测肿瘤免疫治疗效果进行综述。
Abstract: With the application of immune checkpoint inhibitor (ICI) in various malignant tumors, immuno-therapy has become the research focus of tumor treatment. Recently, tumor mutational burden (TMB) has gradually become a reliable biomarker for immunotherapy options for a variety of ma-lignant tumors. This review focuses on the related researches of TMB in the immunotherapy of ma-lignant tumors and its combination with other biomarkers to predict the effect of tumor immuno-therapy.
文章引用：饶舜. 肿瘤突变负荷用于预测恶性肿瘤患者预后的研究进展[J]. 临床医学进展, 2022, 12(8): 7000-7004. https://doi.org/10.12677/ACM.2022.1281008

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.Y., et al. (2016) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. Lancet, 387, 1540-1550. [Google Scholar] [CrossRef] 
[3] Luo, W., Wang, Z., Zhang, T., Yang, L., Xian, J., Li, Y., et al. (2021) Immunotherapy in Non-Small Cell Lung Cancer: Rationale, Recent Advances and Future Perspectives. Precision Clinical Medicine, 4, 258-270. [Google Scholar] [CrossRef] [PubMed]
[4] Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., et al. (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. New England Journal of Medicine, 376, 2415-2426. [Google Scholar] [CrossRef] 
[5] Abdel-Wahab, N., Shah, M. and Suarez-Almazor, M.E. (2016) Ad-verse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Re-ports. PLOS ONE, 11, Article ID: e0160221. [Google Scholar] [CrossRef] [PubMed]
[6] Chung, H.C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., et al. (2019) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 37, 1470-1478. [Google Scholar] [CrossRef] 
[7] 陈冠璇, 宋现让. 肺癌PD1/PD-L1免疫检查点治疗疗效预测标志物第18届世界肺癌大会相关研究综述[J]. 中国肺癌杂志, 2018, 21(9): 697-702.
[8] Wu, H.-X., Wang, Z.-X., Zhao, Q., Chen, D.L., He, M.M., Yang, L.P., et al. (2019) Tumor Mutational and Indel Burden: A Systematic Pan-Cancer Evaluation as Prognostic Biomarkers. Annals of Translational Medicine, 7, Article No. 640. [Google Scholar] [CrossRef] [PubMed]
[9] Goodman, A.M., Kato, S., Bazhenova, L., Patel, S.P., Frampton, G.M., Miller, V., et al. (2017) Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Molecular Cancer Therapeutics, 16, 2598-2608. [Google Scholar] [CrossRef] 
[10] Liu, Y., Huang, K., Yang, Y., Wu, Y. and Gao, W. (2022) Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning. Frontiers in Oncology, 12, Article ID: 906888. [Google Scholar] [CrossRef] [PubMed]
[11] Xu, F., Guan, Y., Zhang, P., Xue, L., Ma, Y., Gao, M., et al. (2022) Tumor Mutational Burden Presents Limiting Effects on Predicting the Efficacy of Immune Checkpoint Inhibitors and Prognostic Assessment in Adrenocortical Carcinoma. BMC Endocrine Disorders, 22, Article No. 130. [Google Scholar] [CrossRef] [PubMed]
[12] Fumet, J.-D., Truntzer, C., Yarchoan, M. and Ghiringhelli, F. (2020) Tumour Mutational Burden as a Biomarker for Immunotherapy: Current Data and Emerging Concepts. European Journal of Cancer, 131, 40-50. [Google Scholar] [CrossRef] [PubMed]
[13] Klebanov, N., Artomov, M., Goggins, W.B., Daly, E., Daly, M.J. and Tsao, H. (2019) Burden of Unique and Low Prevalence Somatic Mutations Correlates with Cancer Survival. Scien-tific Reports, 9, Article No. 4848. [Google Scholar] [CrossRef] [PubMed]
[14] Samstein, R.M., Lee, C.-H., Shoushtari, A.N., Hellmann, M.D., Shen, R., Janjigian, Y.Y., et al. (2019) Tumor Mutational Load Predicts Survival after Immunotherapy across Multiple Cancer Types. Nature Genetics, 51, 202-206. [Google Scholar] [CrossRef] [PubMed]
[15] Cao, D., Xu, H., Xu, X., Guo, T. and Ge, W. (2019) High Tumor Mutation Burden Predicts Better Efficacy of Immunotherapy: A Pooled Analysis of 103078 Cancer Patients. Oncoim-munology, 8, Article ID: e1629258. [Google Scholar] [CrossRef] 
[16] Marcus, L., Fashoyin-Aje, L.A., Donoghue, M., Yuan, M., Rodriguez, L., Gallagher, P.S., et al. (2021) FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mu-tational Burden-High Solid Tumors. Clinical Cancer Research, 27, 4685-4689. [Google Scholar] [CrossRef] 
[17] Cuppens, K., Baas, P., Geerdens, E., Cruys, B., Froyen, G., Decoster, L., et al. (2022) HLA-I Diversity and Tumor Mutational Burden by Comprehensive Next-Generation Se-quencing as Predictive Biomarkers for the Treatment of Non-Small Cell Lung Cancer with PD-(L)1 Inhibitors. Lung Cancer, 170, 1-10. [Google Scholar] [CrossRef] [PubMed]
[18] Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., et al. (2018) Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and An-ti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients with Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 36, 633-641. [Google Scholar] [CrossRef] 
[19] Valero, C., Lee, M., Hoen, D., Zehir, A., Berger, M.F., Seshan, V.E., et al. (2021) Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors with 10 or More Mutations per Megabase. JAMA Oncology, 7, 739-743. [Google Scholar] [CrossRef] [PubMed]
[20] McGrail, D.J., Pilie, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., et al. (2021) High Tumor Mutation Burden Fails to Predict Immune Checkpoint Blockade Response across All Cancer Types. Annals of Oncology, 32, 661-672. [Google Scholar] [CrossRef] [PubMed]
[21] Ready, N., Hellmann, M.D., Awad, M.M., Otterson, G.A., Gutierrez, M., Gainor, J.F., et al. (2019) First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of Clinical Oncology, 37, 992-1000. [Google Scholar] [CrossRef] 
[22] Yarchoan, M., Albacker, L.A., Hopkins, A.C., Montesion, M., Murugesan, K., Vithayathil, T.T., et al. (2019) PD-L1 Expression and Tumor Mutational Burden Are Independent Bi-omarkers in Most Cancers. JCI Insight, 4, Article ID: e126908. [Google Scholar] [CrossRef] [PubMed]
[23] Buder-Bakhaya, K., Hassel, J.C. (2018) Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review from the Melanoma Perspective and Beyond. Frontiers in Immunology, 9, Article No. 1474. [Google Scholar] [CrossRef] [PubMed]
[24] Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. (2015) Cancer Immunology. Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer. Science, 348, 124-128. [Google Scholar] [CrossRef] [PubMed]
[25] Hellmann, M.D., Nathanson, T., Rizvi, H., Creelan, B.C., Sanchez-Vega, F., Ahuja, A., et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 33, 843-852.e4. [Google Scholar] [CrossRef] [PubMed]

为你推荐